Biotech news for Thursday, June 25, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Artfoliophoto/iStock via Getty Images Seeking Alpha Are the shorts right about these companies facing trouble, or are some of these prime candidates for a short squeeze? Discuss which side of the trade you're on in the comments section! Related to this article…
Sophie_James Shah Capital, the largest shareholder of Novavax ( NVAX ), criticized the company’s leadership on Wednesday, even after the COVID-19 vaccine developer managed to get shareholder backing for all resolutions put forward at its annual stockholder mee…
uniQure N.V. ( QURE ) Tuesday reported the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering are expected to b…
PM Images Absci ( ABSI ) is up ~20% in premarket trading Monday after announcing $100M in financing from Eli Lilly ( LLY ) as well as several private equity firms. The biopharma has priced an underwritten offering of 13,495,277 shares at $7.41 per share. Adage…
asbe Absci ( ABSI ) shares added ~21% in the premarket on Wednesday after the company posted early-stage trial data for its hair loss therapy ABS-201 alongside an underwritten stock offering worth about $100M. Citing an interim readout as of June 8, 2026, from…
MoonLake Immunotherapeutics ( MLTX ) said it has priced an underwritten public offering of 9M Class A ordinary shares at $20.00 per share, along with pre-funded warrants to purchase up to 1M additional shares, as the biotechnology company seeks to raise capita…
Andrii Dodonov The U.S. and European regulators have accepted Regeneron’s ( REGN ) marketing applications for cemdisiran, an experimental therapy developed with Alnylam Pharmaceuticals ( ALNY ) for a rare autoimmune condition called myasthenia gravis. After co…
JHVEPhoto/iStock Editorial via Getty Images A federal appeals court has sided with Pfizer ( PFE ) in a patent dispute with Enanta Pharmaceuticals ( ENTA ) over the pharma giant’s COVID-19 therapy Paxlovid. The Court of Appeals for the Federal Circuit ruled tha…